Mazeron R, Petit C, Rivin E, Limkin E, Dumas I, Maroun P, Annede P, Martinetti F, Seisen T, Lefkopoulos D, Chargari C, Haie-Meder C
Radiation Therapy, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France; Molecular Radiotherapy - UMR1030, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
Radiation Therapy, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
Clin Oncol (R Coll Radiol). 2016 Mar;28(3):171-7. doi: 10.1016/j.clon.2015.10.008. Epub 2015 Nov 5.
In locally advanced cervical cancer, the dose delivered results from the sum of external beam radiotherapy and brachytherapy, and is limited by the surrounding organs at risk. The balance between both techniques influences the total dose delivered to the high-risk clinical target volume (HR-CTV). The aim of the present study was to compare the ability of reaching different planning aims after external beam radiotherapy pelvic doses of 45 Gy in 25 fractions or 50.4 Gy in 28 fractions, both considered as standard prescriptions.
The optimised plans of 120 patients treated with pelvic chemoradiation followed by magnetic resonance image-guided intracavitary brachytherapy were reviewed. The doses per pulse were calculated, and the number of pulses required to reach the planning aims, or a limiting dose constraint to organs at risk, was calculated. All doses were converted to 2-Gy equivalents. Three scenarios were applied consisting of different sets of planning aims: 85 and 60 Gy for the HR-CTV and the intermediate-risk CTV (IR-CTV) D90 (minimal dose received by 90% of the volume) in scenario 1, 90 and 60 Gy, respectively, for scenarios 2 and 3. For organs at risk, dose constraints were 90, 75 and 75 Gy to the bladder, rectum and sigmoid D2cm(3), respectively, in scenarios 1 and 2, and 80, 65 and 70 Gy in scenario 3.
A similar HR-CTV D90 could have been reached in scenarios 1 and 2 according to both pelvic doses. In scenario 3, a higher mean HR-CTV could have been reached in the 45 Gy arm (83.5 ± 8.0 versus 82.4 ± 8.0, P < 0.0001). The mean D2cm(3) of organs at risk was systematically and significantly increased after a delivery of 50.4 Gy to the pelvis, from 0.9 to 2.89 Gy. The proportions of plans reaching planning aims were 85.8, 72.5 and 42.5% after 45 Gy and 85.5, 67.5 and 33.3% after 50.4 Gy according to scenarios 1, 2 and 3, respectively. According to scenario 3, 50.4 Gy, the reachable HR-CTV D90 was higher in 30% of the cases, by 2 Gy in two cases. Those cases were unpredictable and due to unfavourable organs at risk topography and poor response to external beam radiotherapy.
The delivery of 45 Gy in 25 fractions to the pelvis before brachytherapy warrants a higher probability to reach brachytherapy planning aims, in comparison with 50.4 Gy in 28 fractions.
在局部晚期宫颈癌中,所给予的剂量是外照射放疗和近距离放疗剂量之和,且受到周围危及器官的限制。两种技术之间的平衡会影响给予高危临床靶区(HR-CTV)的总剂量。本研究的目的是比较在盆腔外照射放疗剂量分别为45 Gy分25次或50.4 Gy分28次(均视为标准处方剂量)后,达到不同计划目标的能力。
回顾了120例接受盆腔放化疗后行磁共振成像引导腔内近距离放疗患者的优化计划。计算每个脉冲的剂量,并计算达到计划目标或危及器官的剂量限制所需的脉冲数。所有剂量均转换为2 Gy等效剂量。应用了三种包含不同计划目标集的方案:方案1中HR-CTV和中危CTV(IR-CTV)的D90(90%体积所接受的最小剂量)分别为85和60 Gy,方案2和3中分别为90和60 Gy。对于危及器官,方案1和2中膀胱、直肠和乙状结肠D2cm(3)的剂量限制分别为90、75和75 Gy,方案3中为80、65和70 Gy。
根据两种盆腔剂量,方案1和2中HR-CTV的D90可达到相似水平。在方案3中,45 Gy组可达到更高的HR-CTV平均剂量(83.5±8.0 vs 82.4±8.0,P<0.0001)。盆腔给予50.4 Gy后,危及器官的平均D2cm(3)系统性且显著增加,从0.9 Gy增至2.89 Gy。根据方案1、2和3,45 Gy后达到计划目标的计划比例分别为85.8%、72.5%和42.5%,50.4 Gy后分别为85.5%、67.5%和33.3%。根据方案3,在50.4 Gy时,30%的病例中可达到的HR-CTV D90更高,其中2例高2 Gy。这些病例不可预测,原因是危及器官的位置不利以及对外照射放疗反应不佳。
与28次分割给予50.4 Gy相比,近距离放疗前盆腔25次分割给予45 Gy更有可能达到近距离放疗计划目标。